Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other financing activities: 2018-2025

Historic Other financing activities for Whitehawk Therapeutics (WHWK) over the last 2 years, with Jun 2025 value amounting to $803,000.

  • Whitehawk Therapeutics' Other financing activities rose 11371.43% to $803,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $5.6 million, marking a year-over-year increase of 4299.22%. This contributed to the annual value of $16,000 for FY2024, which is 90.00% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Other financing activities stood at $803,000 for Q2 2025, which was down 83.35% from $4.8 million recorded in Q1 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Other financing activities peaked at $9.6 million during Q3 2021, and registered a low of -$1,000 during Q4 2024.
  • For the 3-year period, Whitehawk Therapeutics' Other financing activities averaged around $725,125, with its median value being $41,500 (2023).
  • In the last 5 years, Whitehawk Therapeutics' Other financing activities tumbled by 102.94% in 2024 and then surged by 48,120.00% in 2025.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Other financing activities stood at $9.6 million in 2021, then reached $114,000 in 2022, then tumbled by 70.18% to $34,000 in 2023, then tumbled by 102.94% to -$1,000 in 2024, then skyrocketed by 11,371.43% to $803,000 in 2025.
  • Its Other financing activities stands at $803,000 for Q2 2025, versus $4.8 million for Q1 2025 and -$1,000 for Q4 2024.